Suchergebnisse
Suchergebnisse:
About Apotex; Our Leadership; Corporate Responsibility; Press Center; Products; Healthcare Professionals; R & D; Business Opportunities. International Business Development Opportunities; Co-Development; Out-Licensing in EMEA; Submit Your Opportunity; API. API Expertise & Global Presence; Core Competencies; Manufacturing Facilities; Product List ...
- About Us
We improve everyday access to affordable, innovative...
- Products
Products. Apotex currently produces more than 300 generic...
- Healthcare Professionals
Apotex is committed to helping pharmacists meet the...
- R & D
Research at Apotex includes the development of generic,...
- Business Opportunities
Apotex has substantial experience and expertise in...
- Submit Your Opportunity
Apotex would like to hear from you! Call us at Phone:...
- About Us
Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries.
- 1974
- CA$~2 billion in 2018 (in worldwide sales)
- ~8,000 (2023)
www.apotex.com. Stand: 2021. Apotex Inc. (Dachgesellschaft: Apotex Pharmaceutical Holdings Inc.) ist ein kanadisches Pharmaunternehmen mit Hauptsitz in Toronto (Provinz Ontario ). Das 1974 von Barry Sherman (1942–2017) [3] gegründete Unternehmen ist der größte Generika -Hersteller in Händen kanadischer Eigentümer.
17. Mai 2022 · Melbourne, September 20, 2018 – The Australian Competition and Consumer Commission (ACCC) announced this morning that it ‘has decided not to oppose the merger of generic pharmaceutical companies, Arrow and Apotex’ after finding the transaction would not substantially lessen competition in any market. July 14, 2018.
Apotex develops generic, biosimilar and innovative pharmaceuticals with expertise in formulation, chemistry and bioequivalence testing. It has invested over $1 billion in R&D and conducts clinical trials in India.
